Use of placental growth factor for treating ischemic muscle...

Details Use of placental growth factor for treating ischemic muscle... Use of placental growth factor for treating ischemic muscle...

2006-06-21

2010-06-01

Falk, Anne-Marie (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093100, C424S093200

Reexamination Certificate

active

07727971

ABSTRACT:
The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.

REFERENCES:
patent: 5919899 (1999-07-01), Persico et al.
patent: 7105168 (2006-09-01), Carmeliet et al.
patent: 2 332 373 (1999-06-01), None
patent: WO 97/14307 (1997-04-01), None
patent: WO 98/00493 (1998-01-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 98/49300 (1998-11-01), None
patent: WO 99/40197 (1999-08-01), None
Chiocca et al, Gene Therapy for Nuerological Disorders and Brain Tumors, Edited by E. Antonio Chiocca, Humana Press, p. 191-203, 1998.
Eck et al Goodman & Gilman's The Pharmacological basis of Therapeutics, McGraw-Hill, New York, NY. pp. 77-101.
Tio et al, Human Gene Therapy, 10: 2953-2960, 1999.
Khan et al, Gene Therapy, 10: 285-291, 2003.
Autiero et al., “Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Fik1,”Nat. Med. 9(7):936-43 (2003).
Autiero et al., “Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders,”J. Thromb. Haemost. 1(7):1356-70 (2003).
Breier et al., “Expression of Vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation,”Development114(2):521-32 (1992).
Cao et al., “In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor,”J. Clin. Invest. 98(11):2507-11 (1996).
Carmeliet et al., “Abnormal blood vessel development and lethality in embryos lacking a single.VEGF allele,”Nature380(6573):435-9 (1996).
Carmeliet et al., “Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164and VEGF188,”Nat. Med. 5(5):495-502 (1999).
Carmeliet et al., “Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions,”Nat. Med. 7(5):575-83 (2001).
Carmeliet, “VEGF gene therapy: stimulating angiogenesis or angioma-genesis?”Nat. Med. 6(10):1102-3 (2000).
Conn et al., “Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line,”Proc. Natl. Acad. Sci. USA87(4):1323-7 (1990).
Connolly et al., “Human vascular permeability factor: isolation from U397 cells,”J. Biol. Chem. 264(33):20017-24 (1989).
Connolly et al., “Tumor vascular permeability factor stimulates endothelial cell growth and anglogenesis,”J. Clin. Invest. 84(5):1470-8 (1989).
Connolly, “Vascular permeability factor: a unique regulator of blood vessel function,”J. Cell. Biochem. 47(3):219-23 (1991).
Couffinhal et al., “Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor In ApoE −/− mice,”Circulation99(24):3188-98 (1999).
Deindl et al., “Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit,”Circ. Res. 89(9):779-86 (2001).
DiSalvo et al., “Purification and characterization of a naturally occurring vascular endothelial growth factor—placenta growth factor heterodimer,”J. Biol. Chem. 270(13):7717-23 (1995).
Ferrara et al., “The vascular endothelial growth factor family of polypeptides,”J. Cell. Biochem. 47(3):211-8 (1991).
Ferrara and Henzel, “Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells, ”Biochem. Biophys. Res. Commun. 161(2):851-8 (1989).
Folkman and Shing, “Anglogenesis,”J. Biol. Chem. 267(16):10931-4 (1992).
Frelin, “VEGF: a mediation of hypoxic angiogenesis,”Medicine Sciences13(6-7):886-92 (1997).
Gospodarwicz et al., “Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived foillculo stellate cells,”Proc. Natl. Acad. Sci. USA86(19):7311-5 (1989).
Hariawala et al., “VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts,”J. Surg. Res. 63(1)77-82 (1996).
Henry et al., “The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis,”Circulation107(10):1359-65 (2003).
Isner and Asahara, “Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization,”J. Clin. Invest. 103(9):1231-6 (1999).
Klagsbrun and D'Amore, “Regulators of angiogenesis,”Annu. Rev. Physiol. 53:217-39 (1991).
Levy et al., “An endothelial cell growth factor from the mouse neuroblastoma cell line NB41,”Growth Factors2(1):9-19 (1989).
Luttun et al., “Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1,”Nat. Med. 8(8):831-40 (2002).
Maglione et al., “Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor,”Proc. Natl. Acad. Sci. USA88(20):9267-71 (1991).
Michael, “Relationship of skeletal muscle atrophy to functional status: a systematic research review,”Biol. Res. Nurs. 2(2):117-31 (2000).
Ngo et al., “Computational complexity, protein structure prediction, and the Levinthal paradox,”The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14 (eds. Merz and Le Grand), pp. 491-5, Birkhäuser, Boston (1994).
Pipp et al., “VEGFR-1-selective VEGF homologue PIGF Is arteriogenic: evidence for a monocyte-mediated mechanism,”Circ. Res. 92(4):378-85 (2003).
Pettit and Gombotz, “The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals,”Trends Biotechnol. 16(8):343-9 (1998).
Tjwa et al., “VEGF and PIGF: two pleiotropic growth factors with distinct roles in development and homeostasis,”Cell Tissue Res. 314(1):5-14 (2003).
Wells, “Additivity of mutational effects in proteins,”Biochemistry29(37):8509-17 (1990).

Affiliated with

Also associated with

Rating

Use of placental growth factor for treating ischemic muscle... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of placental growth factor for treating ischemic muscle..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of placental growth factor for treating ischemic muscle... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4197576